GLSI
Greenwich Lifesciences Inc
NASDAQ · Biotechnology
$29.00
+3.81 (+15.13%)
Open$25.40
Previous Close$25.19
Day High$29.00
Day Low$24.76
52W High$34.10
52W Low$7.78
Volume—
Avg Volume419.8K
Market Cap401.78M
P/E Ratio—
EPS$-1.46
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+17.4% upside
Current
$29.00
$29.00
Target
$34.05
$34.05
$25.54
$34.05 avg
$45.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 64.12M | 62.89M | 59.76M |
| Net Income | 10.06M | 8.97M | 9.50M |
| Profit Margin | 15.7% | 14.3% | 15.9% |
| EBITDA | 19.32M | 16.62M | 17.12M |
| Free Cash Flow | 7.72M | 11.60M | 9.03M |
| Rev Growth | -9.0% | -7.6% | +0.6% |
| Debt/Equity | 0.70 | 0.55 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |